Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea
· Delayed Price · Currency is KRW 8,350.00
+230.00 (2.83%)
Apr 1, 2025, 3:30 PM KST
Vaxcell-Bio Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 1,899 | 13.72 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 13737.28% | - | - | - | - | Upgrade
|
| Cost of Revenue | 1,537 | 10.44 | 16.43 | 19.37 | 5.39 | Upgrade
|
| Gross Profit | 361.57 | 3.28 | -16.43 | -19.37 | -5.39 | Upgrade
|
| Selling, General & Admin | 8,002 | 6,171 | 5,793 | 3,811 | 2,714 | Upgrade
|
| Research & Development | 6,040 | 4,919 | 2,075 | 1,810 | 1,350 | Upgrade
|
| Other Operating Expenses | 23 | 20.67 | 16.62 | 6.57 | 0.44 | Upgrade
|
| Operating Expenses | 15,443 | 11,510 | 8,196 | 5,885 | 4,250 | Upgrade
|
| Operating Income | -15,081 | -11,507 | -8,213 | -5,904 | -4,255 | Upgrade
|
| Interest Expense | -225.12 | -43.66 | -16.68 | -26.9 | -34.9 | Upgrade
|
| Interest & Investment Income | 2,620 | 1,155 | 421.91 | 322.31 | 109.72 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.51 | -11.69 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2,304 | 259.95 | 982.37 | 846.11 | 196.05 | Upgrade
|
| EBT Excluding Unusual Items | -10,384 | -10,147 | -6,825 | -4,763 | -3,984 | Upgrade
|
| Gain (Loss) on Sale of Investments | -182.7 | -126.84 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -56.65 | - | -0.05 | -0.25 | - | Upgrade
|
| Pretax Income | -10,624 | -10,274 | -6,825 | -4,763 | -3,984 | Upgrade
|
| Net Income | -10,624 | -10,274 | -6,825 | -4,763 | -3,984 | Upgrade
|
| Net Income to Common | -10,624 | -10,274 | -6,825 | -4,763 | -3,984 | Upgrade
|
| Shares Outstanding (Basic) | 23 | 20 | 15 | 15 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 20 | 15 | 15 | 7 | Upgrade
|
| Shares Change (YoY) | 17.03% | 28.80% | 0.68% | 122.02% | 55.35% | Upgrade
|
| EPS (Basic) | -463.00 | -524.00 | -448.34 | -315.00 | -585.00 | Upgrade
|
| EPS (Diluted) | -463.00 | -524.00 | -448.34 | -315.00 | -585.00 | Upgrade
|
| Free Cash Flow | -12,824 | -9,589 | -6,212 | -6,785 | -3,330 | Upgrade
|
| Free Cash Flow Per Share | -558.88 | -489.05 | -408.07 | -448.78 | -488.95 | Upgrade
|
| Gross Margin | 19.04% | 23.90% | - | - | - | Upgrade
|
| Operating Margin | -794.20% | -83851.26% | - | - | - | Upgrade
|
| Profit Margin | -559.45% | -74865.84% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -675.31% | -69872.25% | - | - | - | Upgrade
|
| EBITDA | -13,616 | -11,107 | -7,901 | -5,647 | -4,070 | Upgrade
|
| D&A For EBITDA | 1,466 | 399.68 | 311.34 | 257.25 | 185.31 | Upgrade
|
| EBIT | -15,081 | -11,507 | -8,213 | -5,904 | -4,255 | Upgrade
|
| Advertising Expenses | 409.6 | 77.55 | 38.41 | 2 | 19.76 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.